Hua dao Bio completed nearly 200 million yuan C round of financing

Recently, Zhangjiang Science City cell therapy enterprise Huadao (Shanghai) Biopharmaceutical Co., Ltd. (hereinafter referred to as "Hua Dao Bio") completed nearly 200 million yuan C round of financing, Zhejiang Veritas Holdings Co., Ltd., Chongqing Co., Ltd. Equity Investment Management Co., Ltd., Shanghai Weihui Investment Management Co., Ltd. and Shanghai Houlu Investment Co., Ltd. and other capital investment. The financing is another round of financing for Huado Bio following the RMB100 million B round of strategic financing in July 2019.This financing will be mainly used for the construction and completion of the HD CD19 CAR-T injection phase I clinical trials at hua dao Biological Songjiang Base Phase I project (HD CD19 CAR-T injection pilot base and the industrialization technology production base of the whole industrial chain of cell immunotherapy).Founded in September 2017, Huadao Bio focuses on the development of autologic CAR-T cell therapy products for hematomas and solid tumors, as well as the independent innovation of the entire industry chain of the cell immunotherapy industry. In October 2019, its first cell drug variety CD19-CART cell was approved by the National CDE for clinical trials. In addition, a number of CAR-T products are under development.At present, Hua dao biological CAR-T cell products production industry chain production system, covering engineering bacteria fermentation, granulation purification, virus packaging, virus purification, T cell access, T-cell transmesis and T-cell amplification harvest freezing and other related processes, has completed in line with the GMP standards of CAR slow virus carrier engineering production system development, is further improving the independent intellectual property rights of CAR-T cell preparation engineering preparation system development. (Medical Valley)